Year: 2014
Type: article
Abstract: The International Breast cancer Intervention Study (IBIS-I) is a randomised, placebo-controlled chemoprevention clinical trial of the effects of tamoxifen in a population of women at high risk of developing breast cancer. Jack Cuzick and colleagues' report in The Lancet Oncology1 is an important update of the IBIS-I trial. The achievement of such long-term follow-up (median 16 years), especially with more than 74% of participants remaining masked to randomisation, is commendable.
Source: The Lancet Oncology
Author: Rowan T Chlebowski
Institutions: The Lundquist Institute, Harbor–UCLA Medical Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $7,280
OpenAlex ID: W2000819438